Video

Julie Nangia Discusses the Impact of Hair Loss

Author(s):

Julie Nangia, M.D.

Julia Nangia, M.D., assistant professor at Baylor College of Medicine, discusses the impact that chemotherapy-related hair loss can have on patients with breast cancer.

Julia Nangia, M.D., assistant professor at Baylor College of Medicine, discusses the impact that chemotherapy-related hair loss can have on patients with breast cancer.

When a woman loses her hair, that may not be all that is lost. Hair loss also causes a loss of anonymity that a person is sick. But luckily, hair-preserving cooling caps are becoming more common for patients with cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Image of Dr. D'sa
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Image of doctor.
Early Arterial Thrombosis May Signal Future Cancer Risk
Image of Dr. Deville.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Image of man.
Understanding Unique Treatment Options Across Bladder Cancer Care
Image of kelly.
Preparing For Survivorship After Lymphoma Treatment in AYA PatientsPreparing For Survivorship After Lymphoma Treatment in AYA Patients
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Robotic Kidney Cancer Surgery May Aid Recovery, Spare Kidney Function
Image of Doctor.
Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
Why Relationships are Key When Caring For Patients With MPNs
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Advances in Radiation Improve Precision in Brain Cancer Therapy
Related Content
Itovebi plus Ibrance and Faslodex improved overall survival in patients with HR+, HER2– breast cancer versus placebo: © stock.adobe.com.
May 22nd 2025

Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer

Caroline Seymour
Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of blood cells.
May 21st 2025

FDA’s ODAC Casts Votes on the Use of Certain Treatment Options in Cancer Care

Ryan Scott
The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of two woman with pink ribbon.
May 16th 2025

Samuraciclib Therapy Combo Shows Responses in HR+ Advanced Breast Cancer

Ryan Scott
Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior CDK4/6 inhibitor therapy.
Breast.
May 13th 2025

Understanding the Unique Task of Treating Older Patients With Breast Cancer

Ryan Scott
Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.